Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the diverse applications of low-level laser therapy in aesthetic dermatology, especially for managing alopecia, but notes that comprehensive literature on its effectiveness is lacking.

This study found that miR-339-5p negatively regulates loureirin A-induced differentiation of hair follicle stem cells, potentially impacting skin repair and regeneration by inhibiting the Wnt/β-catenin signaling pathway.

This article introduces a series on low level laser light therapy, focusing on its science, regulatory aspects, and controlled trial methodologies, but reports no new clinical results.

This study found that lipid and acne inhibitive cream improved the skin condition in a rabbit ear acne model, showing significant changes in follicular cornification.

In this study, researchers found that RORA directly regulates the expression of the Bnip3 gene, which is crucial for hair follicle stem cell health, using rat HFSCs as a model. They propose that targeting RORA could modulate HFSC status.

This study found that using a Picosecond IR Laser (PIRL) on mouse skin led to less tissue damage and scarring compared to conventional surgical lasers and tools.

This study reviews the mechanism and potential treatment roles of low-level laser therapy for immune-mediated skin diseases, reporting no new clinical results.

This review discusses the use of Raman spectroscopy to evaluate drug penetration in alopecia treatments and suggests it may be a promising tool for enhancing the effectiveness of laser-assisted drug delivery.

This study examined molecular predictors of ritlecitinib efficacy in treating alopecia areata, highlighting the role of JAK3-dependent inflammation and follicular integrity as important factors in understanding disease mechanisms and potential therapeutic effectiveness.

Low-level laser therapy is a safe and effective treatment for hair loss.

This review discusses various applications of low level laser therapy and argues for a holistic evaluation of patients but reports no new clinical findings.

This study identified the rough coat mutation in mice, but found that LOXL is not the causal gene, although its downregulation might contribute to related phenotypic changes.

This study found that chemical lumbar sympathectomy with 5% phenol effectively treated idiopathic livedo reticularis in most patients, offering a potential long-lasting solution with repeatable efficacy upon recurrence.

In this study, the researchers found that after initial hair regrowth with ritlecitinib in patients with severe alopecia areata, it took a median of 93 days to reach clinical trial-defined scalp hair regrowth, with those responding earlier showing faster progression to desired outcomes.

This study describes characteristics and outcomes for adults initiating ritlecitinib for severe alopecia areata, highlighting increased hair regrowth and physician satisfaction with longer treatment durations, despite ongoing psychosocial impacts like embarrassment and anxiety among patients.

This study reported discovering a novel missense variant in a case of autosomal recessive woolly hair in a 31-year-old Chinese woman, which significantly reduced secretion of the encoded protein, likely leading to disease by impairing its hydrolytic function.

This study suggests that the rs2075876 variant in the AIRE gene may significantly increase susceptibility to alopecia areata in the examined male population.

This study identified miRNAs within the Dlk1-Gtl2 region on chromosome 18 as potential epigenetic regulators of lamb fur traits, with possible implications for the PI3K-AKT signaling pathway.

This study describes the development of a monoclonal antibody, 005-C04, which blocks PRLR-mediated signaling, suggesting its potential for furthering understanding of PRLR's role in health and disease.

In this case report, complete hair regrowth was observed in a patient with autoimmune-related alopecia areata after treatment with a Janus kinase inhibitor, suggesting its potential effectiveness for both genetic and sporadic forms of the condition.

In this randomized, double-blind trial, researchers observed that low-level laser therapy led to significantly greater hair regrowth on treated areas compared to a sham treatment in patients with androgenetic alopecia over 24 weeks, suggesting it as a potentially effective and safe option.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

This article reviews the author's experience and favored techniques for using Radiesse in cosmetic treatments but reports no new clinical trial results.

This study found that activating liver X receptors with an agonist reduced skin fibrosis in experimental models, particularly in inflammation-driven conditions, by inhibiting macrophage infiltration and interleukin-6 release.

In this study involving adult mice, the researchers identified that double-stranded RNA-mediated activation of toll-like receptor 3 stimulates wound-induced hair neogenesis, potentially reflecting mechanisms used in facial rejuvenation treatments.

This study suggests that label-retaining cells in the hair follicle contribute to follicular renewal, indicating a specific role in the hair cycle by proliferating during the late telogen phase.

This study found that patients with severe alopecia areata are willing to accept increased risks of serious infection, cancer, and blood clots when opting for a higher dose of ritlecitinib, valuing the potential for greater hair regrowth efficacy compared to a lower dose.

This study reported that ritlecitinib effectively improved hair regrowth in JAK inhibitor-naïve adolescent patients with severe alopecia areata, achieving significant reductions in SALT scores within 24 weeks, but was less effective for patients who had previously been treated with baricitinib.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

This study observed that some patients with homozygous c.736T>A mutation in LIPH may have mild hypotrichosis with long hairs in adulthood.